Statements (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immune response
|
| gptkbp:administered_with |
rabies vaccine
|
| gptkbp:alternativeName |
gptkb:RIG
gptkb:rabies_antibody |
| gptkbp:ATCCode |
J06BB05
|
| gptkbp:availableOn |
limited in some regions
|
| gptkbp:category |
gptkb:monoclonal_antibody
biological product |
| gptkbp:combines |
rabies vaccine
|
| gptkbp:contraindication |
previous severe allergic reaction to immunoglobulin
|
| gptkbp:cost |
expensive in many countries
|
| gptkbp:discoveredBy |
late 19th century
|
| gptkbp:halfLife |
about 10 days (equine)
about 21 days (human) |
| https://www.w3.org/2000/01/rdf-schema#label |
rabies immunoglobulin
|
| gptkbp:includes |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:indicated_for |
people exposed to rabies who have not been previously vaccinated
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
provides passive immunity to rabies virus
|
| gptkbp:not_indicated_for |
people previously vaccinated against rabies
|
| gptkbp:notEffectiveAgainst |
treatment after symptoms appear
|
| gptkbp:pregnancyCategory |
C (varies by country)
|
| gptkbp:producedBy |
purification from plasma
recombinant technology (in development) |
| gptkbp:riskFactor |
transmission of blood-borne pathogens (very low with modern screening)
|
| gptkbp:routeOfAdministration |
injection
intramuscular injection infiltration around wound |
| gptkbp:sideEffect |
fever
allergic reaction pain at injection site |
| gptkbp:source |
gptkb:human
equine |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
post-exposure prophylaxis of rabies
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:post-exposure_prophylaxis_(PEP)
|
| gptkbp:bfsLayer |
5
|